Efficacy of docetaxel, cisplatin, and 5-fluorouracil chemotherapy for superficial esophageal squamous cell carcinoma
Efficacy of docetaxel, cisplatin, and 5-fluorouracil chemotherapy for superficial esophageal squamous cell carcinoma
复制标题
DOI：
10.1111/dote.12485
复制
发表时间：
2017-02-01
影响因子：
2.6
通讯作者：
Kawano, Tatsuyuki
中科院分区：
文献类型：
--
作者：
Miyawaki, Yutaka;Nakajima, Yasuaki;Kawano, Tatsuyuki
多西他赛、顺铂和5-氟尿嘧啶（DCF）联合化疗对晚期或复发性食管鳞状细胞癌（ESCC）的疗效优于常规化疗方案，有望成为ESCC的标准治疗方案。由于单独使用化疗作为早期癌症的治疗是非常罕见的，DCF对浅表性ESCC的疗效仍然未知。然而，从临床肿瘤学的角度来看，重要的是研究化疗对早期癌症的抗癌疗效，这可能有助于了解癌症对化疗的治疗耐药性的发展。这项回顾性、单中心分析纳入了2007年6月至2013年7月期间接受DCF治疗头颈部同步性鳞状细胞癌的28例浅表性ESCC患者。DCF的有效率为60.7%。在17例被判定为完全缓解的患者中，有14例最终通过随访食管胃镜检查证实局部复发。所有28例患者的中位无进展生存期为6.0个月。DCF的抗癌疗效不依赖于肿瘤进展阶段或局部和转移性肿瘤的体积，而是依赖于个体的药物敏感性。我们的研究结果表明，DCF对浅表性食管鳞状细胞癌的疗效似乎仅限于局部病变和区域淋巴结转移，DCF对早期ESCC的预期效果与晚期、转移或复发性食管癌相似。
The anticancer efficacy of docetaxel, cisplatin, and 5-fluorouracil (DCF) chemotherapy has been reported to be better than that of conventional regimens for advanced or relapsed esophageal squamous cell carcinoma (ESCC), and may become a standard therapy for this disease. Because it is extremely rare for chemotherapy to be administered as treatment for early cancer alone, the efficacy of DCF for superficial ESCC remains unknown. However, from a clinical oncological standpoint, it is important to investigate the anticancer efficacy of chemotherapy for early cancer, which may be useful for understanding the development of treatment resistance against chemotherapy in cancer. This retrospective, single-center analysis included 28 patients with superficial ESCC who received DCF for synchronous head and neck squamous cell carcinoma between June 2007 and July 2013. The response rate to DCF was 60.7%. In 14 of 17 patients who had been judged to have a complete response, local recurrence was eventually confirmed by follow-up esophagogastroduodenoscopy. The median progression-free survival for all 28 patients was 6.0 months. The anticancer efficacy of DCF was not found to be dependent on tumor progression stage or on the volume of local and metastatic tumors but on the drug sensitivity of the individual. Our results suggest that the efficacy of DCF against superficial esophageal squamous cell carcinoma appears to be limited to local lesions and metastases of regional lymph nodes, and the expected effect of DCF for early ESCC is similar to that for advanced, metastatic, or recurrent esophageal cancer.